FIG 6.

Nod agonists fail to increase goblet cell numbers and Muc2 production in naïve, C3GnT-deficient mice. (A) Numbers of PAS⁺ goblet cells in C3GnT^−/− mice treated with both Nod1 and Nod2 agonists (C12-iE-DAP + L18-MDP). There was no significant difference between agonist-treated groups and vehicle-treated controls in C3GnT^−/− mice. (B) Numbers of Muc2⁺ cells, as assessed by immunohistochemistry. (C) Muc2 expression in C3GnT^−/− mouse intestinal tissue following treatment with Nod1 and Nod2 agonists (C12-iE-DAP + L18-MDP) as determined by real-time PCR. (D) Representative immunostaining for murine Muc2 (red) and counterstaining with DAPI (blue) in C3GnT^−/− mice treated with vehicle or Nod1 and Nod2 agonists (C12-iE-DAP + L18-MDP). Magnification, ×200; bars, 100 μm. The Mann-Whitney U test was used to analyze statistical differences among the groups. ns, not significant (5 mice per group).